Fulgent genetics, inc. (FLGT)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Dec'15
Assets
Current assets
Cash and cash equivalents

9,302

11,965

20,522

9,165

5,288

6,736

8,489

3,654

5,274

6,490

9,478

11,473

6,734

7,897

-

489

Marketable securities

18,028

16,304

11,596

17,820

24,139

24,298

24,114

-

-

19,994

-

-

-

-

-

-

Marketable securities

-

-

-

-

-

-

-

26,949

23,211

-

16,570

17,400

20,633

12,971

-

-

Cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

8,205

-

Trade accounts receivable, net of allowance for doubtful accounts of $862 and $751, as of March 31, 2020 and December 31, 2019, respectively

6,371

6,555

5,292

5,543

4,563

5,948

6,077

5,055

4,969

4,005

3,594

4,186

4,601

4,364

4,406

2,118

Other current assets

3,324

2,255

1,795

2,267

2,311

2,561

2,370

2,537

2,621

2,438

2,396

1,668

1,202

906

4,883

314

Current assets of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9

Total current assets

37,025

37,079

39,205

34,795

36,301

39,543

41,050

38,195

36,075

32,927

32,038

34,727

33,170

26,138

17,494

2,930

Marketable securities, long-term

43,294

41,947

11,487

11,697

8,983

6,386

4,250

-

-

14,883

-

-

-

-

-

-

Marketable securities, long term

-

-

-

-

-

-

-

7,460

10,285

-

17,860

17,243

19,643

25,597

-

-

Equity method investments

623

872

909

1,084

1,233

1,512

1,746

1,956

1,692

1,937

2,184

-

-

0

-

-

Fixed assets, net

5,698

5,974

6,396

5,937

6,046

6,446

6,853

7,325

6,853

7,272

6,490

6,737

5,894

6,234

5,178

2,469

Operating lease right-of-use asset

2,525

2,633

2,739

2,756

2,858

-

-

-

-

-

-

-

-

-

-

-

Deferred tax asset

-

-

-

-

-

-

929

592

505

126

-

-

-

54

-

-

Deferred tax asset

-

-

-

-

-

-

-

-

-

-

27

37

44

-

86

-

Other long-term assets

160

251

409

167

231

17

18

20

30

39

71

61

69

17

-

-

Non-current assets of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

433

Total long-term assets

-

-

-

-

-

-

-

-

-

-

-

-

25,650

-

5,264

2,902

Total assets

89,325

88,756

61,145

56,436

55,652

53,904

54,846

55,548

55,440

57,184

58,670

58,805

58,820

58,040

22,758

5,832

Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable

2,855

1,581

2,150

1,175

1,456

1,313

1,024

1,794

1,347

2,089

2,370

1,820

2,306

2,756

3,286

314

Accrued liabilities

2,024

1,333

1,634

1,333

1,354

1,259

1,231

1,184

1,062

911

781

902

745

436

471

199

Income tax payable

56

24

60

-

-

-

-

-

-

-

-

-

230

124

-

-

Contract liabilities

444

365

-

-

-

166

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities, short-term

431

420

409

401

393

-

-

-

-

-

-

-

-

-

-

-

Accumulated losses of unconsolidated companies in excess of investment

-

-

-

-

-

-

-

-

-

-

-

105

-

-

-

-

Other current liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,253

-

Current liabilities of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

173

Total current liabilities

5,810

3,723

4,253

2,909

3,203

2,738

2,255

2,978

2,409

3,000

3,151

2,827

3,281

3,316

5,010

686

Operating lease liabilities, long-term

2,143

2,256

2,366

2,385

2,488

-

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

-

-

-

-

-

14

11

9

6

6

5

2

-

2

-

-

Deferred tax liability

-

-

-

-

-

-

-

-

-

-

243

243

243

243

503

-

Total liabilities

7,953

5,979

6,619

5,294

5,691

2,752

2,266

2,987

2,415

3,006

3,399

3,072

3,524

3,561

5,513

686

Commitments and contingencies (Note 8)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

Stockholders’ equity
Units 56,000 Class D and 51,000 Class P preferred units authorized, issued and outstanding, 44,000 Class D and 49,000 Class P common units authorized and 34,000 Class D and 45,000 Class P common units issued and outstanding, at December 31, 2015 (Note 9)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

58,306

Common stock, $0.0001 par value per share, 50,000 shares authorized, 21,672 and 21,483 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

2

2

2

2

2

2

2

2

2

2

2

2

2

2

1

-

Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding at March 31, 2020 and December 31, 2019

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

Additional paid-in capital

146,948

146,058

117,478

115,532

114,790

114,203

113,600

113,011

112,431

111,884

111,299

-

-

109,734

-

-

Additional paid-in capital

-

-

-

-

-

-

-

-

-

-

-

110,746

110,301

-

73,211

-

Accumulated other comprehensive income (loss)

-193

146

179

203

95

-35

-57

-82

-87

-44

10

-68

-85

-103

-

-

Accumulated deficit

-65,385

-63,429

-63,133

-64,595

-64,926

-63,018

-60,965

-60,370

-59,321

-57,664

-56,040

-54,947

-54,922

-55,154

-55,967

-53,160

Total stockholders’ equity

81,372

82,777

54,526

51,142

49,961

51,152

52,580

52,561

53,025

54,178

55,271

55,733

55,296

54,479

17,245

5,146

Total liabilities and stockholders’ equity

89,325

88,756

61,145

56,436

55,652

53,904

54,846

55,548

55,440

57,184

58,670

58,805

58,820

58,040

22,758

5,832